{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:41:32Z","timestamp":1788252092330,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017951","name":"Health Commission of Qinghai Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011501","name":"Qinghai Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.acra.2025.01.044","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:47:50Z","timestamp":1743169670000},"page":"6751-6760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Y-90 Selective Internal Radiation Therapy for Inoperable,\u00a0Chemotherapy-Resistant Liver Metastases: A Meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Shengxiang","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib1","first-page":"469","article-title":"The role and significance of hepatic environmental cells in tumor metastatic colonization to liver","volume":"54","author":"Jin","year":"2023","journal-title":"2023"},{"key":"10.1016\/j.acra.2025.01.044_bib2","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1097\/MS9.0000000000001241","article-title":"The tendency of segmental distribution of hepatic metastasis according to couinaud classification: a comparison of portal versus systemic route of metastatis due to primary colorectal and breast tumors","volume":"85","author":"Khan","year":"2023","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.acra.2025.01.044_bib3","first-page":"2022","article-title":"Breast cancer liver metastasis: pathogenesis and clinical implications","volume":"12","author":"Liu","year":"2022","journal-title":"Front\u00a0Oncol"},{"issue":"6","key":"10.1016\/j.acra.2025.01.044_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CEJ.0000000000000823","article-title":"The burden and trend of liver metastases in Shanghai, China: a population-based study","volume":"32","author":"Zheng","year":"2023","journal-title":"Eur J Cancer\u00a0Prev Offl\u00a0J\u00a0Eur\u00a0Cancer Prev\u00a0Org"},{"key":"10.1016\/j.acra.2025.01.044_bib5","series-title":"Locoregional Tumor Therapy","first-page":"55","article-title":"CRC Liver Metastases","author":"Peeters","year":"2015"},{"key":"10.1016\/j.acra.2025.01.044_bib6","first-page":"137","article-title":"Oncological management of unresectable liver metastases","volume":"30","author":"Prenen","year":"2012","journal-title":"Dig\u00a0Dis"},{"issue":"10","key":"10.1016\/j.acra.2025.01.044_bib7","first-page":"819","article-title":"Failure of chemotherapy in hepatocellular carcinoma due to impaired and dysregulated primary liver drug metabolizing enzymes and drug transport proteins: what to do?","volume":"19","author":"Ul-Islam","year":"2018","journal-title":"Curr\u00a0Drug Metab"},{"key":"10.1016\/j.acra.2025.01.044_bib8","first-page":"2015","article-title":"Chemotherapy in the setting of severe liver dysfunction in patients with metastatic colorectal cancer","volume":"2015","author":"Kasi","year":"2015","journal-title":"Case\u00a0Rep Oncol Med"},{"issue":"16","key":"10.1016\/j.acra.2025.01.044_bib9","article-title":"Yttrium-90 radioembolization for lung cancer metastases: small institutional experience","volume":"41","author":"Kovalenko","year":"2023","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jso.26223","article-title":"Yttrium-90 radiation segmentectomy for hepatic metastases: a\u00a0multi-institutional study of safety and efficacy","volume":"123","author":"Padia","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.acra.2025.01.044_bib11","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.hpb.2023.05.315","article-title":"Y-90 can cause reliable tumor regression: ready for prime time?","volume":"25","author":"Heard","year":"2023","journal-title":"HPB"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11845-018-1773-6","article-title":"Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases","volume":"188","author":"O'Leary","year":"2019","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-022-09302-z","article-title":"Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.acra.2025.01.044_bib14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","article-title":"Radioembolization with (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study","volume":"7","author":"Fidelman","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"02","key":"10.1016\/j.acra.2025.01.044_bib15","first-page":"138","article-title":"Complications of 90Y radioembolization treatment for liver tumors","volume":"7","author":"Eghbali","year":"2023","journal-title":"Dig\u00a0Dis\u00a0Interv"},{"issue":"10","key":"10.1016\/j.acra.2025.01.044_bib16","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane\u00a0Database\u00a0Syst Rev"},{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib17","first-page":"324","article-title":"Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases","volume":"103","author":"Cosimelli","year":"2010","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.acra.2025.01.044_bib18","unstructured":"A Phase II Clinical Trial Evaluating Overall Survival With Therasphere\u00ae In Conjunction With 2nd-Line FOLFOX In Patients With Gemcitabine-Refractory Pancreatic Carcinoma With Liver Metastases. 2012 2012."},{"key":"10.1016\/j.acra.2025.01.044_bib19","unstructured":"A Phase III Clinical Trial Evaluating TheraSphere\u00ae in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy. 2011 2011."},{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.acra.2025.01.044_bib21","unstructured":"Safety Profile Assessment of TheraSphere\u00ae Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study. 2011 2011;"},{"issue":"8","key":"10.1016\/j.acra.2025.01.044_bib22","first-page":"767","article-title":"Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy","volume":"120","author":"Golfieri","year":"2015","journal-title":"Radiol\u00a0Med"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000109","article-title":"Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study","volume":"40","author":"Xing","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.acra.2025.01.044_bib24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12029-018-0053-z","article-title":"Outcomes of radioembolization in patients with chemorefractory colorectal cancer liver metastasis: a single-center experience","volume":"50","author":"T\u00fcrk","year":"2019","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"10.1016\/j.acra.2025.01.044_bib25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis","volume":"230","author":"Egger","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib26","first-page":"e65","article-title":"Yttrium-90 glass microsphere transarterial radioembolization for patients with unresectable liver-dominant breast cancer metastasis","volume":"108","author":"Rishi","year":"2020","journal-title":"Int\u00a0J\u00a0Radiat\u00a0Oncol\u00a0Biol\u00a0Phys"},{"issue":"5","key":"10.1016\/j.acra.2025.01.044_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2214\/AJR.20.25315","article-title":"Yttrium-90 hepatic radioembolization for advanced chemorefractory metastatic colorectal cancer: survival outcomes based on right- versus left-sided primary tumor location","volume":"217","author":"Wu","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib28","article-title":"Transarterial Yttrium-90 glass microsphere radioembolization of chemotherapy-refractory breast cancer liver metastases: results of a single institution retrospective study","volume":"7","author":"Barakat","year":"2022","journal-title":"Adv Radiat\u00a0Oncol"},{"issue":"1159","key":"10.1016\/j.acra.2025.01.044_bib29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/bjr\/tqae096","article-title":"Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study","volume":"97","author":"Topcuoglu","year":"2024","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1016\/j.acra.2025.01.044_bib30","first-page":"1187","article-title":"Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases","volume":"19","author":"Jakobs","year":"2008","journal-title":"J\u00a0Vasc\u00a0Interv\u00a0Radiol"},{"issue":"6","key":"10.1016\/j.acra.2025.01.044_bib31","first-page":"1179","article-title":"Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases","volume":"32","author":"Cianni","year":"2009","journal-title":"Cardiovasc\u00a0Interv\u00a0Radiol"},{"issue":"5","key":"10.1016\/j.acra.2025.01.044_bib32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","article-title":"Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases","volume":"251","author":"Saxena","year":"2010","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.acra.2025.01.044_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2298\/VSP1104341A","article-title":"Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center","volume":"68","author":"Arslan","year":"2011","journal-title":"Vojnosanit Pregl"},{"issue":"5","key":"10.1016\/j.acra.2025.01.044_bib34","first-page":"1066","article-title":"Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases","volume":"35","author":"Seidensticker","year":"2012","journal-title":"Cardiovasc\u00a0Interv\u00a0Radiol"},{"issue":"7","key":"10.1016\/j.acra.2025.01.044_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069448","article-title":"Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases","volume":"8","author":"Smits","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.acra.2025.01.044_bib36","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jvir.2014.07.007","article-title":"Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy","volume":"25","author":"Gordon","year":"2014","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.acra.2025.01.044_bib37","first-page":"1296","article-title":"Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients","volume":"21","author":"Saxena","year":"2014","journal-title":"Ann\u00a0Surg\u00a0Oncol"},{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib38","first-page":"794","article-title":"Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients","volume":"22","author":"Saxena","year":"2015","journal-title":"Ann\u00a0Surg\u00a0Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib39","first-page":"20","article-title":"Use of yttrium-90 radioembolization for patients with unresectable liver metastases: experience from a single center","volume":"5","author":"Bhangoo","year":"2016","journal-title":"Transl\u00a0Cancer Res"},{"issue":"4","key":"10.1016\/j.acra.2025.01.044_bib40","first-page":"608","article-title":"A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres(\u00ae) versus SIR-Spheres(\u00ae) alone in chemotherapy-resistant colorectal cancer liver metastases","volume":"8","author":"Cho","year":"2017","journal-title":"J Gastrointest\u00a0Oncol"},{"issue":"9","key":"10.1016\/j.acra.2025.01.044_bib41","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/jgh.13752","article-title":"Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors","volume":"32","author":"Jia","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.acra.2025.01.044_bib42","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/cancers16132401","article-title":"The impact of local control on overall survival after Y-90 selective internal radiotherapy of liver metastases in oligometastatic cancer: a retrospective analysis","volume":"16","author":"Yeakel","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.acra.2025.01.044_bib43","first-page":"S202","article-title":"Abstract No. 552 hepatotoxicity and survival in patients with cirrhotic hepatocellular carcinoma versus liver metastatic disease after Yttrium-90 radioembolization","volume":"35","author":"Rao","year":"2024","journal-title":"J\u00a0Vasc\u00a0Interv\u00a0Radiol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.044_bib44","first-page":"620","article-title":"Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure","volume":"39","author":"Entezari","year":"2022","journal-title":"Int\u00a0J\u00a0Hyperther"},{"issue":"2","key":"10.1016\/j.acra.2025.01.044_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijrobp.2005.12.051","article-title":"Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience","volume":"65","author":"Kennedy","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acra.2025.01.044_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/1471-2407-14-497","volume":"14","author":"Dutton","year":"2014","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.acra.2025.01.044_bib47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.01.044_bib48","series-title":"Cancer Regional Therapy: HAI, HIPEC, HILP, ILI, PIPAC and Beyond","first-page":"27","article-title":"Y-90 radiomicrosphere therapy: principles and clinical use in colorectal cancer liver metastases","author":"Gulec","year":"2020"},{"issue":"4","key":"10.1016\/j.acra.2025.01.044_bib49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12094-023-03299-y","article-title":"Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review","volume":"26","author":"Gonz\u00e1lez-Flores","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.acra.2025.01.044_bib50","first-page":"1129","article-title":"A prospective phase II study of safety and efficacy of sorafenib followed by 90Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma","author":"Kaseb","year":"2021","journal-title":"J\u00a0Hepatocell\u00a0Carcinoma"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225000996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225000996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:00:31Z","timestamp":1763326831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225000996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1076633225000996"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.044","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Y-90 Selective Internal Radiation Therapy for Inoperable,\u00a0Chemotherapy-Resistant Liver Metastases: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}